NCT03378479 - Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

March 31, 2020

Study Completion Date

March 30, 2021

Conditions

Aspergillosis; Pulmonary, Invasive (Etiology)

Interventions

DRUG

SOC +Posaconazole 18 MG/ML (milligram/milliliter)

.2\*300mg/d IV on day 1, followed by 1\*300mg/d IV from day 2 for 7 days (total 7 days)

OTHER

standard of care (SOC)

treatment for influenza pneumonia at the investigators discretion

Trial Locations (12)

3000

UZ Leuven, Leuven

3015

MC Erasmus, Rotterdam

5042

Elisabeth-TweeSteden Hospital, Tilburg

6229

UMC Maastricht, Maastricht

6500

UMC Radboud, Nijmegen

6532

Canisius Wilhelmina Hospital, Nijmegen

8000

AZ Sint Jan, Bruges

8800

AZ Delta, Roeselare

9000

UZ Gent, Ghent

59000

CHU Lille, Lille

75010

Hospital Lariboisière, Paris

Hospital Saint-Louis, Paris

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Universitaire Ziekenhuizen KU Leuven

OTHER